**Abstract**

**Background:** Brexpiprazole is a serotonin-dopamine activity modulator that acts as a partial agonist at 5-HT1A and dopamine D2 receptors, and an antagonist at 5-HT2A and noradrenaline alpha1B/2C receptors, all at similar potencies. The efficacy, safety, and tolerability of brexpiprazole were evaluated in patients with acute schizophrenia, based on pooled data from two pivotal phase III studies (NCT01396421\[1\] and NCT01393613\[2\]).

**Methods:** In two similarly designed studies, patients with acute schizophrenia were randomly assigned to fixed once-daily doses of brexpiprazole 2mg, 4mg or placebo (an additional treatment group was included in each study \[0.25mg and 1.0mg\] to evaluate the lower dose range; these doses were not included in the meta-analysis). Primary efficacy endpoint was change in PANSS total score from baseline to week 6; key secondary endpoint was the change in CGI-S score at week 6.

**Results:** Pooled brexpiprazole 4mg (N=359) and 2mg (N=359) were each superior to placebo (N=358) in change from baseline in PANSS total score at week 6 (least square mean difference \[LSMD\] to placebo: -6.69, p\<0.0001 and -5.46, p=0.0004, respectively). Results of the key secondary endpoint supported the primary results.

Altogether 8.2% (30/364) and 7.1% (26/368) of brexpiprazole-treated patients (4mg and 2mg, respectively) vs 14.7% (54/368) placebo-treated patients discontinued due to adverse events. The incidences of insomnia and agitation in the brexpiprazole treatment groups were similar or lower than with placebo. Akathisia incidences were 6.9% and 4.6% in the brexpiprazole 4mg and 2mg groups, respectively, vs 4.6% with placebo and sedation incidences were 2.7% and 1.6% in the brexpiprazole 4mg and 2mg groups, respectively, vs 0.8% with placebo.

**Conclusion:** Pooled data from two pivotal studies provide evidence that brexpiprazole is efficacious and safe in treating patients with acute schizophrenia. Both brexpiprazole 2 and 4mg were well tolerated, with notably low levels of akathisia and sedation.
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